文献速递关节外科

代谢综合征是否影响初次全膝关节置换术后再手术、翻修或并发症的风险

Does Metabolic Syndrome Impact the Risk of Reoperation, Revision, or Complication After Primary Total Knee Arthroplasty?
PubMed 文献 · J Arthroplasty · 2022-09-03

本研究利用机构全关节登记数据,将2063例符合世界卫生组织标准的代谢综合征患者行初次全膝关节置换术的病例,按年龄、性别和手术年份1:1匹配至无代谢综合征患者。结果显示两组5年免于任何再手术、任何翻修及假体周围感染再手术的假体生存率无显著差异;但代谢综合征且BMI>40的患者5年免于任何翻修和假体周围感染再手术的生存率显著降低。作者认为肥胖是代谢综合征标准中的重要独立危险因素。

要点

  • 代谢综合征患者与无代谢综合征患者5年免于任何再手术、任何翻修及假体周围感染再手术的生存率无显著差异。
  • 代谢综合征且BMI>40患者5年免于任何翻修生存率95% vs 98%,风险比2.1,P=0.005。
  • 代谢综合征且BMI>40患者5年免于假体周围感染再手术生存率97% vs 99%,风险比2.2,P=0.02。

核心结论

  • 代谢综合征未显著增加全膝关节置换术后任何再手术的风险;然而代谢综合征且BMI>40的患者任何翻修和假体周围感染再手术的风险约为两倍。
  • 作者认为肥胖是代谢综合征标准中的重要情况,且仍是独立危险因素。

研究设计与样本

  • 利用机构全关节登记数据,纳入2063例根据世界卫生组织标准诊断代谢综合征并接受初次全膝关节置换术的患者。
  • 代谢综合征患者按年龄、性别和手术年份1:1匹配至无代谢综合征患者。
  • 采用世界卫生组织体重指数分类评估代谢综合征患者中肥胖的影响;采用Kaplan-Meier法确定假体生存率;临床结局采用膝关节学会评分评估;平均随访5年。
  • 证据等级:3级,病例对照研究。

主要发现

  • 代谢综合征与非代谢综合征患者5年免于任何再手术的假体生存率无显著差异(P=0.7)。
  • 代谢综合征与非代谢综合征患者5年免于任何翻修的假体生存率无显著差异(P=0.2)。
  • 代谢综合征与非代谢综合征患者5年免于假体周围感染再手术的假体生存率无显著差异(P=0.2)。
  • 代谢综合征且BMI>40患者5年免于任何翻修生存率为95% vs 98%,风险比=2.1,P=0.005。
  • 代谢综合征且BMI>40患者5年免于假体周围感染再手术生存率为97% vs 99%,风险比=2.2,P=0.02。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic syndrome (MetS) is an increasingly frequent condition characterized by insulin resistance, abdominal obesity, hypertension, and dyslipidemia. This study evaluated implant survivorship, complications, and clinical outcomes of primary TKAs performed in patients who have MetS. METHODS: Utilizing our institutional total joint registry, 2,063 primary TKAs were performed in patients with a diagnosis of MetS according to the World Health Organization criteria. MetS patients were matched 1:1 based on age, sex, and surgical year to those who did not have the condition. The World Health Organization's body mass index (BMI) classification was utilized to evaluate the effect of obesity within MetS patients. Kaplan-Meier methods were utilized to determine implant survivorship. Clinical outcomes were assessed with Knee Society scores. The mean follow-up was 5 years. RESULTS: MetS and non-MetS patients did not have significant differences in 5-year implant survivorship free from any reoperation (P = .7), any revision (P = .2), and reoperation for periprosthetic joint infection (PJI; P = .2). When stratifying, patients with MetS and BMI >40 had significantly decreased 5-year survivorship free from any revision (95 versus 98%, respectively; hazard ratio = 2.1, P = .005) and reoperation for PJI (97 versus 99%, respectively; hazard ratio = 2.2, P = .02). Both MetS and non-MetS groups experienced significant improvements in Knee Society Scores (77 versus 78, respectively; P < .001) that were not significantly different (P = .3). CONCLUSION: MetS did not significantly increase the risk of any reoperation after TKA; however, MetS patients with BMI >40 had a two-fold risk of any revision and reoperation for PJI. These results suggest that obesity is an important condition within MetS criteria and remains an independent risk factor. LEVEL OF EVIDENCE: Level 3, Case-control study.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Ledford CK, Kumar AR, Guier CG, et al. Does Metabolic Syndrome Impact the Risk of Reoperation, Revision, or Complication After Primary Total Knee Arthroplasty? J Arthroplasty. 2022. PMID: 36064093. doi:10.1016/j.arth.2022.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。